Business
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardiomyopathyNon-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, often leading to heart transplantationNo approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan,
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardiomyopathy","length":258,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, often leading to heart transplantation","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"No approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan, and is characterized by weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss","length":244,"tagName":"p"}]},{"val":[{"type":"text","content":"Laromestrocel, a mesenchymal stem cell therapy, has delivered positive initial results across two clinical trials in aging-related frailty","length":138,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":762,"olType":false},{"type":"text","content":"MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Canadian Intellectual Property Office (CIPO) has granted a patent covering administration of laromestrocel (LOMECEL-B®), the Company’s proprietary mesenchymal stem cells (MSCs), for the treatment of patients with symptoms of aging-related frailty and also for the treatment of non-ischemic dilated cardiomyopathy (NIDCM).","length":561,"tagName":"p"},{"type":"text","content":"Canadian Patent No. 3043594, entitled “Method of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity,” pr...